Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Beats on EPS, Stock Up 0.53%

Ligand Pharmaceuticals reported a better-than-expected EPS, which contributed to a slight increase in their stock price. The positive surprise in earnings reflects the company's solid performance, although the lack of revenue data and future guidance may leave investors cautious. The stock's modest gain suggests that investors are encouraged by the earnings beat but are still looking for more clarity on future growth prospects.